読み込み中
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
前日終値
$4.47
+$0.04 · +0.90%
日中の時刻はETです。市場データは遅延する場合があります。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日中レンジ
現在 $4.47
52週レンジ
現在 $4.47
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
54
まちまち
リスク
82
極めて高いリスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
日中レンジ
現在 $4.47
52週レンジ
現在 $4.47
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 85.6万 USD | 130.6万 USD | 287.9万 USD | 134.7万 USD | 106.9万 USD |
| 売上原価 | 22.5万 USD | 80万 USD | 68.3万 USD | 32.2万 USD | 3.3万 USD |
| 粗利益 | 63.1万 USD | 50.6万 USD | 219.6万 USD | 102.5万 USD | 103.6万 USD |
| 研究開発 | 218.6万 USD | 181.5万 USD | 164.1万 USD | 280.3万 USD | 199万 USD |
| 販売・一般管理 | 543.8万 USD | 580.5万 USD | 613.2万 USD | 626.8万 USD | 364.3万 USD |
| 営業費用 | 938万 USD | 782.2万 USD | 796.9万 USD | 840.5万 USD | 576.8万 USD |
| 受取利息 | 20.7万 USD | 42.1万 USD | — | 124万 USD | 1.8万 USD |
| 支払利息 | 1.1万 USD | 3万 USD | 9000 USD | 3.6万 USD | 1.2万 USD |
| 減価償却費と償却費 | 23.4万 USD | 48.2万 USD | 53.8万 USD | 18.7万 USD | 3.3万 USD |
| 営業利益 | −874.9万 USD | −731.6万 USD | −577.3万 USD | −738万 USD | −576.8万 USD |
| 純利益 | −1217.9万 USD | −628.4万 USD | −512.2万 USD | −259.2万 USD | −580.1万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年3月4日 | 1:9 | — | — |
株式分割 | 2025年7月3日 | 1:21 | — | — |
株式分割 | 2023年9月28日 | 1:26 | — | — |
発効済み 2026年3月4日
1:9
発効済み 2025年7月3日
1:21
発効済み 2023年9月28日
1:26
この株式へのエクスポージャーを報告している上場投資信託です。
Avantis Emerging Markets Equity ETFAVEM128.09万—284.09億 USD0.33%$94.11+0.93%
Avantis Emerging Markets Value ETFAVES21.49万0.01%15.67億 USD0.36%$65.56+1.09%
Avantis Emerging Markets Small Cap Equity ETFAVEE12.62万0.09%1.4億 USD0.42%$69.865+0.98%
Avantis Emerging Markets ex-China Equity ETFAVXC12.28万0.03%4.69億 USD0.33%$82.1546+0.51%Avantis Emerging Markets Equity ETFAVEMAvantis Emerging Markets Value ETFAVESAvantis Emerging Markets Small Cap Equity ETFAVEEAvantis Emerging Markets ex-China Equity ETFAVXCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
